Get your weekly dose of everything in the news about incretin mimetic therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
Dave Knapp Man On The Mounjaro
Donate to On The Pen: The Weekly Dose
The On The Pen: The Weekly Dose podcast is a fantastic addition to Dave's repertoire of content. As someone who follows him on Instagram but prefers a podcast format, I was thrilled when he announced the launch of this show. It provides the perfect opportunity for me to stay informed and entertained while I'm driving or cleaning. Right from the first episode, it is evident that the production quality is top-notch. The sound is crisp and clear, making for an enjoyable listening experience. Additionally, the inclusion of hyperlinks in the episode notes is greatly appreciated as it allows me to easily access additional resources mentioned during the show.
One of the best aspects of The On The Pen podcast is Dave's ability to simplify complex concepts related to healthcare and make them accessible to anyone. In a field that can often be overwhelming with intricate details, he does an excellent job of breaking down information so that even those without a medical background can understand it. This approach makes his content valuable to a wide range of listeners who are seeking knowledge and empowerment.
Another commendable aspect of this podcast is Dave's fair and unbiased reporting. While there are often controversial topics in healthcare, he remains neutral and presents information objectively. This allows listeners to form their own opinions based on facts rather than feeling swayed by personal biases or agendas.
While it's challenging to find any major flaws in this podcast, one minor criticism would be that some episodes may not cater specifically to individual interests or needs. However, given the variety of topics covered in each episode, it is understandable that not every segment will resonate with every listener. Nevertheless, Dave's engaging style and ability to deliver information effectively compensate for any potential lack of interest in specific topics.
In conclusion, The On The Pen: The Weekly Dose podcast is a must-listen for anyone looking for accessible and informative healthcare content. Dave's dedication to keeping his audience updated with accurate facts while maintaining an engaging delivery style sets this podcast apart. I highly recommend jumping on board early to join the ever-growing community of listeners who appreciate the valuable knowledge and motivation that Dave delivers.
Topics We Cover: 00:00 – New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 – A new oral triple agonist shows record-setting absorption rates 07:00 – Fractal Health's Revita procedure: weight maintenance after stopping GLP-1s 12:00 – Zepbound vial prices drop (full breakdown by dose) 16:00 – Dave's personal experience switching off Mounjaro and intense hunger return 22:00 – Novo Nordisk's EVOKE/EVOKE+ Alzheimer's trial: what the data really means 29:00 – Why GLP-1 neurological research is just getting started 33:00 – Updates on access, partners, and major news coming soon for Medicare patients If you're on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor. Bullet Point Summary of the Podcast Episode New Obesity Measurement Data (Harvard/Mass General Study) Harvard and Mass General propose adding waist circumference to BMI to better diagnose obesity. Traditional BMI misses key factors like muscle mass and body composition. Using the updated measure, Americans classified as obese jumps from ~43% to almost 69%. This means 7 out of 10 U.S. adults would now qualify as having the disease of obesity. Dave notes this validates many people who “feel” metabolically unwell despite a “normal” BMI. Reinforces his claim that “most people should be talking to their doctors about GLP-1s.” New Oral Triple Agonist (Ascletis – ASC41/ASC? Molecule) From Ascletis (A-S-C-L-E-T-I-S), developing an oral triple agonist targeting: GLP-1 GIP Glucagon Similar in mechanism to retatrutide, expected around 2027. Preclinical (animal) data show stunning results: Oral bioavailability of 4.2% 9× higher than tirzepatide 30× higher than oral semaglutide 6× higher than oral retatrutide 57× greater drug exposure than oral retatrutide Half-life ~56 hours Stronger receptor activation than retatrutide in vitro Suggests potential for the first powerful oral triple agonist—worth watching. ️ 3. Discussion of the Gray Market / TikTok Experience Dave briefly recounts losing his TikTok account and landing in an algorithm filled with teenagers promoting gray-market “retatrutide.” Expresses concern over unregulated peptide sales, especially to minors. Fractal Health's New Data – Weight Maintenance After Stopping GLP-1s New results from the Reveal One study (Fractal Health). Participants: lost 24% of body weight on GLP-1s → stopped injections → got one Revita procedure. At 6 months post-GLP-1 discontinuation: Weight changed only 1.5% (vs. ~10% regain in typical off-drug trials) HbA1c barely shifted Safety profile clean Suggests possible long-term weight maintenance without injections through gut mucosal re-lining. Dave describes his own recent attempt to switch drugs and significant hunger return. Food Noise & Biologic Hunger Dave discusses how stopping Mounjaro caused terrifying, primal hunger. Describes the distinction between: Food noise (brain-based thoughts) Hunger signals (biological/animalistic) Reinforces why many patients cannot maintain weight loss without support. Zepbound (Tirzepatide) Cash-Pay Price Reductions Eli Lilly drops cash-pay vial pricing: 2.5 mg: $349 → $299 5 mg: $499 → $399 7.5–15 mg: $499 → $449 Community feedback (informal poll): Most say still too high to leave compounded versions. Many would switch to branded if price hit $200–$300. Dave notes the Most Favored Nations agreement will push GLP-1 prices toward $250/month within 24 months. Alzheimer's Study (Novo Nordisk – EVOKE & EVOKE+) Oral semaglutide (Rybelsus, 14 mg) did not slow Alzheimer's clinical progression. Biomarkers improved but daily function and cognitive decline did not improve vs placebo. Important context: Oral Rybelsus is a weak form of semaglutide; stronger versions (like Wegovy 2.4 mg or upcoming high-dose oral Wegovy) not tested. Weight loss is not desirable in Alzheimer's patients, influencing drug selection. Dave emphasizes: This was a nearly $700M trial and an act of scientific courage. This is NOT the end of GLP-1 Alzheimer's research. Future molecules may target neurological pathways without suppressing appetite. Mentions Lilly's brenipatide, a GIP receptor agonist being developed for: Addiction Opioid dependency Possibly asthma ️ 8. Access, Cost, and Patient Empowerment Highlights Shed as a partner offering telehealth GLP-1 access. Notes many patients hide GLP-1 use from their primary care doctors. Reinforces OTP's mission: better, more honest conversations with clinicians. Shapa (Numberless Scale) & Dave's Personal Update Dave explains how the Shapa numberless scale helped him stay engaged during weight fluctuations. Finds stepping on “zones” (green/gray/blue) less emotionally damaging than numbers. Closing Notes Promises upcoming Eli Lilly savings card update. Encourages subscribing, liking, and enabling notifications for algorithm visibility. Thanks OTP community for amplifying patient-centric obesity medicine news. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Follow Us Everywhere: https://www.otplinks.com Sign up for Emails: https://www.obesity.news Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Het Exclusive OTP Discounts! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get Exclusive OTP Savings! Https://www.otplinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Exclusive OTP Savings HTTPS://www.otplinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
EXCLUSIVE SAVINGS FOR YOU! www.OTPLinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
GET EXCLUSIVE OTP SAVINGS! www.OTPLinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
VIEW EXCLUSIVE OTP SAVINGS! http://otplinks.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
GET ACCESS TO OBESITY CARE AND MEDS AND SUPPORT OTP: https://lddy.no/1ndi6 USE CODE: OTP25 VISIT ALL OUR LINKS: https://linktr.ee/manonthemounjaro Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Visit our Sponsors and check out EXCLUSIVE OTP Savings! www.OTPLinks.com www.tryshed.com (use code OTP25 to save 25%) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
SUPPORT OUR WORK: OTPLinks.com
View All My Links: https://www.OTPLinks.com Join Ethan's Live: 2way.tv/ethansuplee Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
otplinks.com stallybrand.com (code OTP10) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
otplinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
https://linktr.ee/manonthemounjaro Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
https://linktr.ee/manonthemounjaro Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
View All Our Links and Resources! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Visit All Our Links https://linktr.ee/manonthemounjaro GLP-1 Heart Study https://onthepen.substack.com/p/new-study-glp-1-drugs-protect-the
Visit our links: https://linktr.ee/manonthemounjaro
Links referenced in podcast: https://linktr.ee/manonthemounjaro
https://linktr.ee/manonthemounjaro
Visit All Our Links: https://linktr.ee/manonthemounjaro
VISIT ALL OUR LINKS: https://linktr.ee/manonthemounjaro
VISIT OUR LINKS: https://linktr.ee/manonthemounjaro
Visit Our Links: https://linktr.ee/manonthemounjaro
VISIT ALL OUR LINKS: https://linktr.ee/manonthemounjaro
Visit Our Links: https://linktr.ee/manonthemounjaro
All Our Links: https://linktr.ee/manonthemounjaro Obesity Newsletter: https://www.obesity.news https://onthepen.substack.com/p/stunning-news-zepbound-shrinks-breast https://onthepen.substack.com/p/semaglutide-risk-recent-iowa-study
All Referenced Links: https://linktr.ee/manonthemounjaro
This week, Dave covers massive GLP-1 news out of Connecticut, a new GLP-1 heart study that changes the conversation, and a big OTP event opportunity announcement!
https://www.getclaimable.com/otp Code OTP10 Saves 10% Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro
Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro
https://www.getclaimable.com/otp Code OTP10 Saves 10% Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro #zepbound #insurance #cvscaremark
Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro
At 650 pounds, GLP-1 injections helped give Jamie His Life Back. Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro
SUPPORT OUR WORK AND GET MORE NEWS! https://linktr.ee/manonthemounjaro
https://www.linktr.ee/manonthemounjaro Ozempic rare eye disease update The the race for once monthly dosing Big insurance wins incoming?!
VIEW ALL OF OUR LINKS: https://linktr.ee/manonthemounjaro JOIN OUR SUBSTACK: HTTP://WWW.ONTHEPEN.SUBSTACK.COM
Join the Substack here: onthepen.substack.com Get all my links here: https://linktr.ee/manonthemounjaro
Joe's Petition + All My Links: https://linktr.ee/manonthemounjaro
Dave discussed the latest update in the OFA vs FDA compound tirzepatide battle, as well as this weeks news in obesity medicine. Find our substack and all promotional links here: https://linktr.ee/manonthemounjaro
CVS announces major partnership with Novo Nordisk as Lilly announces Q! 2025 earnings. Dave covers it all in today's breakdown. Join the Substack: https://substack.com/@onthepen WAYS TO SUPPORT MY WORK ⬇️
Join the Substack: https://substack.com/@onthepen WAYS TO SUPPORT MY WORK ⬇️
WAYS TO SUPPORT MY WORK ⬇️
The Knapp family was featured in a health.com video! Watch it Here: https://www.health.com/beyond-obesity-glp1-8685599 WAYS TO SUPPORT MY WORK ⬇️
The Knapp family was featured in a health.com video! Watch it Here: https://www.health.com/beyond-obesity-glp1-8685599 WAYS TO SUPPORT MY WORK ⬇️
The Knapp family was featured in a health.com video! Watch it Here: https://www.health.com/beyond-obesity-glp1-8685599 WAYS TO SUPPORT MY WORK ⬇️
WAYS TO SUPPORT MY WORK ⬇️
WAYS TO SUPPORT MY WORK ⬇️
© 2020-2025 Ivy Podcast Discovery LLC
